-
Natco Pharma's Q3 net profit falls 14% to Rs 196 crore
The company's total income during the quarter under review stood at Rs 1,053 crore, up 10% from Rs 958 crore in the year-ago period.
-
Natco Pharma inks pact with US firm to develop generic oncology drug
The tie-up with Natco Pharma, which has a robust track record of developing complex oncology drugs, will help us meet the growing demand for affordable generic oncology medicines.
-
Natco Pharma receives USFDA approval for generic version of cancer drug
The approval of this ANDA will allow Natco Pharma to market the generic version of Torisel in the US, offering patients a more affordable treatment option.
-
Natco Pharma receives USFDA nod for generic Lenalidomide capsules
Natco Pharma has received final approval from the United States Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Lenalidomide capsules in the strength of 2.5 mg, 5 mg, 10 mg, 15 mg, and 25 mg.
-
Natco Pharma launches generic Tamiflu in the US
Natco Pharma has launched its generic version of Tamiflu (oseltamivir phosphate) capsules in the United States. The company's generic product is available in 30 mg and 75 mg capsule strengths.
-
Natco Pharma gets DCGI nod for generic Sofosbuvir and Velpatasvir tablets
Natco Pharma has received approval from the Drug Controller General of India (DCGI) to manufacture and market its generic versions of Sofosbuvir and Velpatasvir tablets.
-
Natco Pharma receives USFDA nod for generic drug for heart ailments
The company received the final approval for generic Diltiazem HCl Extended-Release Capsules in the strengths of 60 mg, 90 mg, 120 mg, 180 mg, 240 mg, and 300 mg.
-
Natco Pharma Q3 net profit falls 44% to Rs 138 crore
The company's revenue from operations declined by 13.5% to Rs 576.1 crore during the quarter under review.
-
Natco Pharma arm gets USFDA nod for generic drug to treat HIV
The company's US-based arm Natco Pharma Inc has received the final approval from the US health regulator for generic Atripla tablets, used for the treatment of HIV-1 infection in adults and pediatric patients.
-
Natco Pharma launches generic version of Merck's blockbuster cancer drug Keytruda
The company has launched the drug, Pembrolizumab, under the brand name 'Natcolizumab' in the Indian market.
-
Natco Pharma Q2 net profit rises 17% to Rs 160 crore
The company's revenue from operations rose by 10.5% to Rs 597.6 crore during the quarter under review.
-
Add Natco Pharma, target price Rs 1145: ICICI Securities
Natco Pharma Ltd., incorporated in the year 1981, is a Mid Cap company (having a market cap of Rs 18515.48 Crore) operating in Pharmaceuticals sector.
-
Natco Pharma's Ibrexafungerp gets tentative approval in EU
The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorization for Natco Pharma's Ibrexafungerp (formerly known as SCY-078). Ibrexafungerp is an intravenous (IV) antifungal indicated for the treatment of adult patients with invasive aspergillosis and mucormycosis.
-
Natco Pharma Q3 net profit rises 10% to Rs 220 crore
Natco Pharma on Thursday reported a 10% increase in its consolidated net profit to Rs 220.02 crore for the third quarter ended December 2022.
-
Natco Pharma gets USFDA nod for generic version of Revlimid
Natco Pharma has received final approval from the US Food and Drug Administration (USFDA) to market Lenalidomide capsules, a generic version of Revlimid, in the strengths of 5 mg, 10 mg, 15 mg, and 25 mg.
-
Add Natco Pharma, target price Rs 1145: ICICI Securities
Natco Pharma Ltd., incorporated in the year 1981, is a Mid Cap company (having a market cap of Rs 18515.48 Crore) operating in Pharmaceuticals sector.
-
Natco Pharma gets USFDA nod for generic version of breast cancer injection
Hyderabad-based Natco Pharma on Monday said it has received final approval from the US health regulator for its generic version of Ibrance, used for the treatment of breast cancer.
-
Natco Pharma's Q3 net profit jumps to Rs 161 crore
Natco Pharma on Thursday reported a consolidated net profit of Rs 161.05 crore for the third quarter ended December 2022, driven by higher revenue.
-
Natco Pharma gets USFDA nod for generic version of cancer drug Lynparza
Natco Pharma on Thursday said it has received final approval from the US health regulator for its generic version of Lynparza, used for the treatment of certain types of cancer.